Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Besim Ogretmen and Terry Day.
Connection Strength

0.702
  1. The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020. Cancers (Basel). 2020 Jun 11; 12(6).
    View in: PubMed
    Score: 0.193
  2. mTOR inhibitor use in head and neck squamous cell carcinoma: A meta-analysis on survival, tumor response, and toxicity. Laryngoscope Investig Otolaryngol. 2020 Apr; 5(2):243-255.
    View in: PubMed
    Score: 0.190
  3. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
    View in: PubMed
    Score: 0.104
  4. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 2007 Oct 18; 256(1):101-11.
    View in: PubMed
    Score: 0.079
  5. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther. 2006 Jun; 317(3):1188-99.
    View in: PubMed
    Score: 0.072
  6. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem. 2004 Oct 22; 279(43):44311-9.
    View in: PubMed
    Score: 0.065
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.